220 results about "Mucus" patented technology

The invention relates to lactobacillus reuteri HC1602 as well as a fungicide and application thereof, and belongs to the technical field of microorganisms. The lactobacillus reuteri HC1602 is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.26890, the preservation date is March 23, 2023, and the address of the preservation institution is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The invention further provides application of the lactobacillus reuteri HC1602 in preparation of products for inhibiting and preventing respiratory syncytial viruses and application of the lactobacillus reuteri HC1602 in preparation of products for reducing cholesterol in blood. The lactobacillus reuteri HC1602 provided by the invention can be used for effectively inhibiting the invasion of RSV (Respiratory Syndrome Virus) to A549 lung cells and improving the survival rate of the A549 cells.

Modular mucosal tissue bioreactors combined with bioartificial mucus provide a high-fidelity, medium-throughput platform for evaluating CF treatments and modeling host-pathogen biology, a stepping stone towards better options for HEMT-nonresponsive patients. Whole lung ex vivo Cystic Fibrosis model system allows for investigation of candidate CF therapies.

The invention belongs to the technical field of microbial fermentation, and discloses lactobacillus mucilaginosus and application thereof in preparation of a uric acid reducing preparation. The survival rate of the fermented lactobacillus mucus in simulated gastric juice with the pH value of 2.0 for 3 hours is greater than 92%, the survival rate in simulated intestinal juice environment containing 0.5% of cholate is greater than 86%, and the viability of the fermented lactobacillus mucus is obviously higher than that of a conventional strain; and the tea has the effects of reducing uric acid, resisting oxidation and inhibiting pathogenic bacteria. The xanthine oxidase inhibition rate of the natural medicinal and edible compound potion obtained by mixing and co-fermenting the strain and existing bacterial powder is greater than 77% (45% or more higher than that of an unfermented group), and the oxidation resistance after fermentation can be improved by 50% at the same time. The beverage is suitable for being drunk as a daily functional food for a long time, and provides a natural and healthy collaborative diet relieving scheme for patients with hyperuricemia and gout.

The invention discloses lactobacillus mucus YF28 and application thereof, and belongs to the technical field of microorganisms. The fermented lactobacillus mucus YF28 is separated from Hu sheep manure, is classified and named as the fermented lactobacillus mucus YF28, and has the preservation number of CCTCC (China Center For Type Culture Collection) NO: M 20252433. The fermented lactobacillus mucilaginosus YF28 has good tolerance in the gastrointestinal environment and can reach the intestinal tract to play a role. The bacterial strain has strong intestinal adhesion capacity, is easy to form a probiotic biological membrane, and is beneficial to intestinal health. The fermented lactobacillus mucus YF28 can promote peristalsis, enrich the abundance of Akkermansia bacteria and bacteriophage thereof, restore the water content of excrement to a normal level, and significantly promote intestinal health. The invention has an application prospect in the development of drugs or health-care foods with the function of relieving constipation and related gastrointestinal symptoms.

The invention belongs to the technical field of biological medicine, and particularly relates to eutectic gel, a preparation method thereof and application of the eutectic gel in promoting mucous membrane drug delivery. The invention provides eutectic gel. The eutectic gel comprises a eutectic solvent and a polymer solution, the eutectic solvent comprises a hydrogen bond acceptor and a hydrogen bond donor; the polymer solution is selected from one or more of a gelatin solution, a polyvinyl alcohol solution, a polyethylene solution or a pyrrolidone solution. The eutecticevaporate gel provided by the invention can realize rapid and tight adhesion and continuous administration on mucous membranes which continuously secrete mucus, and has the following advantages: tight adhesion can be formed on mucous membranes with dynamically updated mucus, so that the residence time of an administration system on the mucous membranes is prolonged; and a drug delivery channel is established by penetrating through a mucous layer, so that the drug is efficiently and continuously delivered to mucous membrane tissues. The deep eutectic gel effectively solves the problem that an existing mucous membrane drug delivery system is low in drug delivery efficiency.

Devices, systems, and methods for high frequency chest wall oscillation (HFCWO) therapy can enhance expectoration by preferred impact to the user to encourage mucus dislodging, including by successive pressure imposition by a chest engagement device to provide HFCWO.

The invention belongs to the technical field of biochemistry, and particularly relates to a probiotic composition for relieving depression as well as a preparation method and application of the probiotic composition. The probiotic composition is prepared from bacillus cecum, lactobacillus reuteri and an oligosaccharide composition; wherein the viable count of the bacillus cecum and the lactobacillus reuteri is 10 < 9 >-10 < 11 > CFU / g; the oligosaccharide composition is prepared by compounding polydextrose, fructo-oligosaccharide and galactooligosaccharide according to an optimized weight ratio. According to the invention, the oligosaccharide composition is cooperated with the probiotics to play a curative effect, so that the proliferation effect of the bacteroides cecum and the lactobacillus reuteri in the intestinal tract is improved, and the balance of the probiotics in the intestinal tract is regulated. Detection results of behavioristics and physiological indexes of mice show that the depression-like behaviors of the mice are remarkably reduced under the action of the composition, and various biochemical indexes are remarkably improved; the composition has a certain improvement effect on depressive mood.

The invention discloses a lactobacillus mucus fermentation strain. The microbial preservation number of the lactobacillus mucus fermentation strain is CCTCC (China Center for Type Culture Collection) NO: M 20252262. The strain can inhibit enterotoxigenic escherichia coli, and can treat or slow down diarrhea, intestinal oxidative damage, intestinal inflammation damage, intestinal morphological damage, intestinal barrier function damage and intestinal flora disorder caused by the enterotoxigenic escherichia coli. The strain is a probiotic with a clinical application prospect.

The invention belongs to the technical field of biology, and particularly relates to a complex microbial inoculant for promoting formation of a biological membrane, a microcapsule and application of the complex microbial inoculant. The complex microbial inoculant comprises lactobacillus mucus fermentation FMBL L24016DMX with the preservation number of CCTCC NO: M20241583 and bifidobacterium longum subsp. Longum FMBL B241770LS with the preservation number of CCTCC NO: M 20241993, the complex microbial inoculant can grow on a culture medium containing prebiotics, the biofilm formation amount is the highest when the complex microbial inoculant is co-cultured in a culture medium containing isomaltooligosacharide, the complex microbial inoculant is prepared into a single-layer microcapsule or a double-layer microcapsule, and the complex microbial inoculant can be used for preparing the probiotics. The endophytic fungus has good embedding rate and viable count, can resist gastrointestinal environment, has good heat resistance, and has wide application prospects.

The invention belongs to the field of medicines, and particularly relates to application of a cough relieving agent in preparation of an anti-influenza virus medicine. Through the synergistic effects of resisting viruses, resisting inflammation, regulating mucus secretion and inhibiting nerve sensitization, the antitussive agent relieves influenza symptoms and promotes recovery from the source, has the advantages of being stable in curative effect, small in toxic and side effect, not prone to generating drug resistance, not capable of promoting virus variation and the like, is wider in application stage and application crowd, and can intervene in the early stage of influenza infection. Due to the fact that the antitussive agent can treat influenza caused by exogenous cold and influenza viruses, the antitussive agent can be used in time to relieve symptoms when cough, excessive phlegm and other symptoms are found in the early stage of a patient, the antitussive agent can relieve the exogenous cold for a non-influenza patient, and the antitussive agent can prevent influenza from being converted into severe influenza from mild influenza for an influenza patient. And the reduction of the treatment effect caused by definite diagnosis delay and oseltamivir treatment delay is also avoided.

This invention discloses a quantitative detection kit for arginine peptidase, a qualitative detection kit for arginine peptidase, and their usage methods. The quantitative detection kit utilizes the specific substrate Nα-benzoyl-DL-arginine-4-ylbenzamide hydrochloride, which can be hydrolyzed by arginine peptidase to 4-ylbenzamide. 4-ylbenzamide has a maximum absorption peak at 405 nm, and the specific arginine peptidase activity can be rapidly detected at room temperature using spectrophotometry. The qualitative kit utilizes the specific substrate Nα-benzoyl-DL-arginine-β-naphthamide hydrochloride, which can be hydrolyzed by arginine peptidase to p-β-naphthamide. β-naphthamide combines with 4-(dimethylamino)cinnamaldehyde to form a compound that is visible to the naked eye as a pink color. The disulfide bond cleaving agent cuts the mucus disulfide bonds, exposing bacterial enzyme sites, and the synergistic effect of the enzyme activator enhances the reaction rate of arginine peptidase hydrolysis of the substrate, significantly improving the detection sensitivity of arginine peptidase in tongue coating samples.

The invention provides application of pinostrobin in preparation of a medicine for treating gastric ulcer, and belongs to the technical field of biological medicine. The pinostrobin provided by the invention realizes the anti-gastric ulcer effect by improving the gastric mucosa blood flow volume, inhibiting inflammatory reaction, inhibiting oxidation reaction and maintaining the integrity of the gastric mucus barrier. Pinostrobin can reduce the gastric ulcer area of rats and increase the pain threshold value; the content of ET-1 in plasma is reduced, and the repairing effect of gastric mucosa is enhanced; the contents of TNF-alpha and IL-6 are reduced, the content of IL-10 is increased, and the anti-inflammatory effect is enhanced; the content of T-SOD in plasma is increased, the content of MPO is reduced, and the antioxidant effect is enhanced. The pinostrobin is expected to be used as a new medicine for treating gastric ulcer.

An application aid (10) suitable for assisting a user in applying an adhesive base plate (20) of an ostomy device to a skin surface around a user's stoma, the adhesive base plate including a first adhesive surface (30) facing the skin and a second surface (40) facing away from the skin, the application aid being configured to be removably attached to the base plate and adapted to at least partially surround the user's stoma during application of the base plate to the skin surface around the user's stoma, the application aid including a base portion (70) and a protective member (80) disposed on a surface of the base portion and adapted to prevent mucus from the stoma mucosa from contaminating the base plate during application of the base plate to the skin surface around the user's stoma.

The utility model discloses a fly maggot breeding material collecting machine head assembly device which comprises a movable guide rail plate, one end of the movable guide rail plate is connected to one end of a base through threads, the movable guide rail plate is provided with a material collecting and cleaning mechanism, and the material collecting and cleaning mechanism comprises a servo motor. The upper end of the servo motor is fixedly installed on a fixing plate, the lower end of the fixing plate is installed at the upper end of a movable guide rail plate, a lead screw is installed at the lower end of the servo motor, through the servo motor, a telescopic hydraulic cylinder and a first scraping plate, automatic cleaning work can be achieved, manual intervention is reduced, and the working efficiency is improved. A first scraper 204 can effectively scrape fly maggots or wastes accumulated in the culture tank box 102, so that the environment in the culture tank is ensured to be clean, the wastes are prevented from being accumulated to influence culture, mucus secreted by the body surfaces of the fly maggots is prevented from being attached to the surface of the culture tank, and part of the fly maggots still attached to the surface of the culture tank is reduced; and the fly maggot and waste material collecting effect is improved.

The invention relates to the technical field of biological preparations, and discloses a periodontitis improving compound preparation containing fermented lactobacillus mucus and traditional Chinese medicine extracts, and the periodontitis improving compound preparation comprises the following raw materials: an oral preparation: fermented lactobacillus mucus CQPC202403 bacterial powder; the gel comprises scutellaria baicalensis, honeysuckle, salvia miltiorrhiza, liquorice and a hydrogel matrix; the preservation number of the lactobacillus mucus CQPC202403 in the China General Microbiological Culture Collection Center (CGMCC) is CGMCC NO.31106, and the preservation date of the lactobacillus mucus CQPC202403 is June 27, 2024. The lactobacillus mucilaginosus adopted by the invention inhibits pathogenic bacteria through competitive rejection and immunoregulation; the traditional Chinese medicine extracts such as the radix scutellariae directly destroy bacterial pellicles, and the radix scutellariae and the traditional Chinese medicine extracts cooperate with each other, so that the antibacterial effect is enhanced on the premise of not causing drug resistance.

The invention belongs to the technical field of probiotics and application of the probiotics, and particularly discloses a strain of lactobacillus fermentum 121 and a preparation method of the lactobacillus fermentum 121. The strain is preserved in the China General Microbiological Culture Collection Center (CGMCC) on August 8, 2025, and the preservation number is CGMCC No.35547. The lactobacillus mucilaginosus 121 has remarkable oxidation resistance, and can be subjected to biological fermentation to generate quercetin. The compound can be used for developing health-care food, cosmetics and oral beauty products for preventing and / or relieving skin oxidative damage and / or aging, and has a wide application prospect.

The application belongs to the technical field of microorganisms and fermentation engineering, and particularly relates to a fermented Lactobacillus muci genus with a function of delaying aging and application thereof. The bacterium was preserved in the Guangdong Microbial Culture Collection Center on August 27, 2025, and the preservation number is GDMCC No: 66877. Experimental results show that the bacterium has excellent antioxidant performance, can relieve oxidative damage, delay aging, inhibit the expression of aging-related genes, and has the ability to improve the memory reproduction ability decline caused by aging, improve the body's anti-inflammatory ability, improve the intestinal flora imbalance induced by aging, and can regulate the level of fat factors, improve energy metabolism, and has the potential of anti-fat deposition and protection of liver function. Therefore, the bacterium can be used to develop products with multiple beneficial functions such as delaying aging, helping to antioxidant, auxiliary improving memory, helping to regulate intestinal flora, and has the advantages of high safety, strong gastrointestinal tolerance, good colonization ability, and has good application value.

The invention provides application of an Slc36a1 agonist in preparation of a medicine for preventing and / or treating colitis, and belongs to the technical field of biology. According to the invention, 4-GBA or sarcosine is applied to a colitis model mouse, and clinical and histological phenotypes of DSS-induced colitis can be significantly improved. According to experiments of colonic organs and mice, 4-GBA enhances intestinal mucosal barrier and promotes intestinal homeostasis by up-regulating Slc36a1. According to the invention, 4-GBA or sarcosine molecules targeting Slc36a1 are taken as a core, and the limitation of an existing treatment strategy is broken through by synchronously solving a linkage mechanism of stem cell regeneration-goblet cell differentiation-mucous barrier repair.

The application discloses Lactobacillus reuteri and application thereof in preparation of a medicine for treating diffuse large B-cell lymphoma, and relates to the technical field of biological medicine. The application provides application of Lactobacillus reuteri and / or a metabolite thereof in preparation of a medicine for treating diffuse large B-cell lymphoma, wherein the Lactobacillus reuteri is Lactobacillus reuteri (HG001). Limosilactobacillus reuteri The Lactobacillus reuteri is separated from feces of healthy people and used for preparation of the medicine for treating diffuse large B-cell lymphoma, and it is found that the Lactobacillus reuteri is confirmed as a probiotic strain for enhancing the chemotherapy effect of diffuse large B-cell lymphoma and can improve side effects caused by cyclophosphamide treatment of diffuse large B-cell lymphoma; and the Lactobacillus reuteri and the cyclophosphamide have a synergistic effect in treatment of diffuse large B-cell lymphoma.

The invention relates to an operation device, in particular to a portable anorectal operation auxiliary device which comprises a handheld gun handle, a gun barrel and an exploring tube, the hollow gun barrel is connected to the front end of the handheld gun handle, a guide hole is horizontally formed in the upper portion of the handheld gun handle, the front end of the guide hole is communicated with an opening in the rear end of the gun barrel, and the exploring tube can slide into the gun barrel through the guide hole. The front end of the exploring tube is connected with a probe. In the aspect of cleaning the camera, the water pipe and the annular nozzle are arranged at the position of the probe, when the device is externally connected with a water source, water flows through the water pipe and is evenly sprayed out of the annular nozzle, the camera can be cleaned in time, intestinal wall mucus or dirt interference of a patient is avoided, clear imaging is guaranteed, operation cleaning does not need to be interrupted, and medical operation efficiency is greatly improved. Meanwhile, the device is provided with a distraction mechanism, the closed probe can be protected, friction damage between the closed probe and the intestinal wall is reduced, the internal space can be slightly distraction and expanded according to the anorectal condition of a patient, the passing rate of the probe is increased, convenient conditions are created for subsequent medical operation, and the device has practicability and innovativeness.

Accessories for a nasal aspiration device, comprising: - an accessory body (10) suitable for grasping; wherein the accessory body comprises: - a compressed air inlet channel (16) suitable for fluid communication with a compressed air generator (200) to obtain an airflow with a positive pressure, wherein the compressed air inlet channel (16) defines a constriction (16c) to generate a Venturi effect; - a suction channel (20) extending into the constriction (16c) and in fluid communication with a mucus inlet channel (14) such that a negative pressure is generated in the mucus inlet channel (14) by the Venturi effect, suitable for suctioning the mucus; - a mucus collection chamber (30) formed in the accessory body (10) which is in fluid communication with the mucus inlet channel (14); - an end nozzle (12) arranged at a distal end of the accessory body (10) and suitable forto be inserted at least partially into a user's nostril, wherein the mucus inlet channel (14) is formed in the end nozzle, wherein the suction channel (20) runs outside the mucus collection chamber (30) and characterized in that the end nozzle (12) is removably coupled to the accessory body (10) by means of a calibrated interference, wherein the calibrated interference is selected such that the end nozzle detaches from the accessory body when a positive pressure is generated in the accessory body which is higher than a certain limit value.

The application discloses a stomach-derived limosilactobacillus fermentum LAF-09 and application thereof, and the preservation number of the stomach-derived limosilactobacillus fermentum LAF-09 is GDMCC No. 65656. The inventor of the application screens a stomach-derived limosilactobacillus fermentum LAF-09 from stomach mucosa tissue of healthy people, the strain has strong acid resistance and high proliferation capacity in the stomach, has strong adhesion properties to stomach epithelial GSE-1 cells, can be effectively applied to prevent and treat gastric ulcers caused by indomethacin, and has no obvious side effects.

The invention provides a method for detecting eosinophilic granulocyte peroxidase and application thereof, and relates to the technical field of biological detection.The method comprises the steps that a respiratory tract sample and a sample treatment reagent are mixed, dispersion treatment and centrifugation are conducted, supernatant is taken, and a to-be-detected sample is obtained; carrying out magnetic particle chemiluminescence detection on a to-be-detected sample, and judging the content of eosinophilic granulocyte peroxidase according to a luminescence signal value obtained by detection, the final pH value of the reaction system is 8.0-12.0 according to the detection of a light-emitting signal value; the sample treatment reagent is an aqueous solution containing 0.06-0.12% w / v of a reducing agent. The technical prejudice that the EPX detection is interfered by the peroxidase activity of the EPX in the prior art is overcome; and meanwhile, the mucus is uniformly dispersed through dispersion treatment by virtue of a sample treatment reagent containing a reducing agent, so that high-sensitivity and high-specificity full-automatic detection of the respiratory tract sample EPX is realized on the magnetic particle chemiluminescence platform for the first time.

The application discloses a kind of biological hybrid micro machine population oral delivery system of imitating Helicobacter pylori survival mechanism, belong to oral stomach medicine delivery technical field.The system is by active power module (flagellum driven chlamydomonas reinhardtii), environmental regulation module (acid urease modified on algal surface) and multifunctional load module (macrophage membrane wrapped drug-loaded nanoparticles) synergistic assembly through polydopamine (PDA) spatial conformation control layer is formed.Active power module utilizes self-movement ability to penetrate mucus barrier and extend intracavity retention time to 12 hours or more;Environmental regulation module produces local alkalization effect by catalyzing urea hydrolysis, provides chemical shield for system in extremely acid environment of pH 1.0-3.0, protects active power module from gastric acid inactivation;Multifunctional load module is accurately delivered to gastric epithelial cells by inflammation targeting effect, such as CRISPR / Cas9 biological macromolecule, and realizes up to 31.8% in-vivo gene editing efficiency.The application provides a non-invasive, modular active delivery platform for the precise treatment of gastric diseases such as gastritis through the synergistic effect of physical penetration, metabolic reprogramming and gene intervention.

The present invention relates to a multi-epitope antigen comprising 20 epitope masses of from 20 to 36 amino acids, from a protein selected from the group consisting of NanA, PcsB, PhtD, Ply, PncO, StkP, PspA-F1 and PspA-F2. In addition, the invention relates to an immunogenic composition comprising said antigen and a pharmaceutically acceptable vehicle and / or adjuvant. In addition, the invention also discloses a pneumococcus diagnostic kit, which comprises the antigen combined with a detectable fraction or a bioactive fragment thereof; an antibody generated from the antigen; and instructions for use. Furthermore, the invention relates to the use of said antigens for the preparation of vaccines for the prevention of diseases caused by pneumococcal bacteria and for the production of monoclonal and polyclonal antibodies. Finally, the present invention relates to an in vitro diagnostic method of pneumococci comprising contacting said antigen bound to a detectable fraction or a biologically active fragment thereof with a sample of bodily fluids selected from mucus and urine expelled from blood, lower respiratory tract.

An amphiphilic drug carrier and the use thereof in the ocular delivery of a biomacromolecular drug. The amphiphilic drug carrier is capable of penetrating the ocular mucus barrier, loading a biomacromolecular drug by means of non-covalent interaction, and delivering the biomacromolecular drug for the treatment of fundus diseases.

The application discloses a fermenting limosilactobacillus DACN611 (Limosilactobacillus fermentum DACN611) with a preservation number of CCTCC NO: M 20232522 and application of the fermenting limosilactobacillus DACN611 in preparation of a product for relieving alcoholism and protecting liver, which not only expands the application range of the fermenting limosilactobacillus DACN611 and improves the utilization value, but also provides a new fermenting limosilactobacillus capable of significantly improving the symptoms of alcoholism of a host, significantly degrading ethanol and acetaldehyde in the host, having a rapid alcohol relief effect and having a wide market application prospect.

This invention relates to the field of biomaterials, specifically to the application of an acidic hydrolysate of a giant salamander mucus extract in the preparation of a root surface treatment agent. The root surface treatment agent comprises a product obtained by reducing lyophilized powder of salamander skin secretions with an acidic solution at a concentration of 0.2-0.3 mol / L and a pH of 1-5, wherein the mass ratio of the lyophilized salamander skin secretions to the acidic solution is (1-3):1; the resulting root surface treatment agent, after adjustment with an alkaline solution, has a pH of 6-6.5. This root surface treatment agent demonstrates significant potential in promoting natural tooth replantation and restoration, with effects including promoting early load stabilization through natural wet bonding, assisting in the construction of a regenerative microenvironment through active proteins, and promoting adhesion between periodontal ligament stem cells and the matrix by enhancing adhesion signal expression.